Doxorubicin is active in lower concentrations, but the tested compounds should be considered as having dual activity: H3R antagonists/inverse agonists, and cytotoxicity against MDA-MB-231, and MCF-7 (breast cancer) cells. The gene discussed is HRH3; the disease is breast carcinoma.